Linagliptin alleviates fatty liver disease in diabetic db/db mice

AIM: To study the effects of linagliptin on the structural signs of non-alcoholic fatty liver disease (NAFLD) in db/db mice. METHODS: Male diabetic db/db mice (BKS.Cg-Dock7(m+)/(+)Lepr(db)/J) aged 10 wk received the dipeptidyl peptidase 4 (DPP4) inhibitor linagliptin (10 mg/kg) or saline as a placeb...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:World J Diabetes
Main Authors: Michurina, Svetlana V, Ishenko, Irina Ju, Klimontov, Vadim V, Archipov, Sergey A, Myakina, Natalia E, Cherepanova, Marina A, Zavjalov, Eugenii L, Koncevaya, Galina V, Konenkov, Vladimir I
Format: Artigo
Jezik:Inglês
Izdano: Baishideng Publishing Group Inc 2016
Teme:
Basic Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5107713/
https://ncbi.nlm.nih.gov/pubmed/27895822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v7.i19.534
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki